Business
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the appointment of Andrew Scott as Vice President of Corporate Communications. In this new role, Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, while supporting the Company’s licensing and partnership initiatives. “We are thrilled t
About this update from Turn Therapeutics Inc.
[{"type":"image","alt":"Turn Therapeutics","displaySize":"","headline":null,"caption":"Turn Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/2e45caf24b7062b91032e0e4351b1e39"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uTv2v5jICXhGET5aPRSD4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2e45caf24b7062b91032e0e4351b1e39","width":300,"height":101}},"lazy":false},{"type":"text","content":"LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the appointment of Andrew Scott as Vice President of Corporate Communications. In this new role, Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, while supporting the Company’s licensing and partnership initiatives.","length":506,"tagName":"p"},{"type":"text","content":"“We are thrilled to welcome Andrew to this newly created senior executive role. His addition comes as Turn Therapeutics enters a new phase of growth following its public listing and strengthened balance sheet. Andrew brings a wealth of experience that will help guide us as a public company, expand our investor engagement and ensure our story reaches the right audiences as we approach several important milestones in the coming year, including the completion of our Phase 2 clinical program,” said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. “We look forward to Andrew’s guidance as we continue executing on partnerships and advancing our clinical development efforts.”","length":706,"tagName":"p"},{"type":"text","content":"With over 30 years of experience in capital markets and corporate finance, Mr. Scott joins Turn Therapeutic from ThinkEquity LLC where he was a Managing Director of Investment Banking. Previously, he served as Vice President of Business Development at Fortress Biosciences, Inc. Over the course of his career, he has helped raise approximately $3 billion across a wide range of transactions within the life-sciences sector. Mr. Scott received a BBA in Accounting from Pace University.","length":499,"tagNa...